Yue Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yue Zhong has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Nian-Guang Li
National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China
3 shared publications - Wen-Yu Wu
Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
3 shared publications - Shao-Peng Yu
The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2 shared publications - Ting Gu
National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China
2 shared publications - Ying Sun
National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China
2 shared publications - Yu-Ting Lu
National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China
2 shared publications
Latest Publications
- 29 June 2018
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2018 (24) , 3075-3085
Norbornene‐Mediated Palladium‐Catalysed Domino‐Type Catellani Reaction: an Efficient and Regiospecific Acylation/Suzuki Coupling of Aryl Iodides
The Catellani reaction is a domino reaction catalysed by palladium/norbornene. It can be used for the synthesis of a range of aromatic compounds in one step, and is of great interest in the synthesis of natural products and drugs. In this paper, we report a palladium/norbornene‐catalysed ortho‐acylation/ipso‐Suzuki coupling reaction of aryl iodides using acyl chlorides as acylating agents and arylboronic acids as quenching reagents. The reactions were carried out using readily available starting materials, and ortho‐aryl benzophenones were obtained in moderate to good yields. Compared with previous Catellani reactions, this reaction has a wider substrate scope, shorter reaction times, and higher yields of the target compounds.
- 29 June 2018
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2018 (24) , 3075-3085
Norbornene‐Mediated Palladium‐Catalysed Domino‐Type Catellani Reaction: an Efficient and Regiospecific Acylation/Suzuki Coupling of Aryl Iodides
The Catellani reaction is a domino reaction catalysed by palladium/norbornene. It can be used for the synthesis of a range of aromatic compounds in one step, and is of great interest in the synthesis of natural products and drugs. In this paper, we report a palladium/norbornene‐catalysed ortho‐acylation/ipso‐Suzuki coupling reaction of aryl iodides using acyl chlorides as acylating agents and arylboronic acids as quenching reagents. The reactions were carried out using readily available starting materials, and ortho‐aryl benzophenones were obtained in moderate to good yields. Compared with previous Catellani reactions, this reaction has a wider substrate scope, shorter reaction times, and higher yields of the target compounds.
- Open Access
Synthesis and Bioactivity Characterization of Scutellarein Sulfonated Derivative
Scutellarin (1) has been widely used to treat acute cerebral infarction in clinic, but poor aqueous solubility decreases its bioavailability. Interestingly, scutellarin (1) could be metabolized into scutellarein (2) in vivo. In this study, a sulfonic group was introduced at position C-8 of scutellarein (2) to enhance the aqueous solubility of the obtained derivative (3). DPPH (1,1-diphenyl-2-picrylhydrazyl)-radical scavenging ability and antithrombic activity were also conducted to determine its bioactivity. The result showed that scutellarein derivate (3) could be a better agent for ischemic cerebrovascular disease treatment.
Open AccessSynthesis and Bioactivity Characterization of Scutellarein Sulfonated Derivative
Scutellarin (1) has been widely used to treat acute cerebral infarction in clinic, but poor aqueous solubility decreases its bioavailability. Interestingly, scutellarin (1) could be metabolized into scutellarein (2) in vivo. In this study, a sulfonic group was introduced at position C-8 of scutellarein (2) to enhance the aqueous solubility of the obtained derivative (3). DPPH (1,1-diphenyl-2-picrylhydrazyl)-radical scavenging ability and antithrombic activity were also conducted to determine its bioactivity. The result showed that scutellarein derivate (3) could be a better agent for ischemic cerebrovascular disease treatment.
- Open Access
Development and Structural Modification of BACE1 Inhibitors
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder which usually occurs in the elderly. The accumulation of β-amyloid and the formation of neurofibrillary tangles are considered as the main pathogenies of AD. Research suggests that β-secretase 1 (BACE1) plays an important role in the formation of β-amyloid. Discovery of new BACE1 inhibitors has become a significant method to slow down the progression of AD or even cure this kind of disease. This review summarizes the different types and the structural modification of these new BACE1 inhibitors.
Open AccessDevelopment and Structural Modification of BACE1 Inhibitors
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder which usually occurs in the elderly. The accumulation of β-amyloid and the formation of neurofibrillary tangles are considered as the main pathogenies of AD. Research suggests that β-secretase 1 (BACE1) plays an important role in the formation of β-amyloid. Discovery of new BACE1 inhibitors has become a significant method to slow down the progression of AD or even cure this kind of disease. This review summarizes the different types and the structural modification of these new BACE1 inhibitors.